After the GEMINI-ACS-1 trial

Yılmaz, Mehmet Birhan

Journal Metrics

Impact Factor (2022): 0.8
CiteScore (2022): 1.2
Source Normalized Impact
per Paper: 0.22
SCImago Journal Rank: 0.348

52/3Current Issue Ahead of Print Archive Most Accessed Articles

Quick Search

In authors and

In titles and abstracts

In keywords

In all

pdf

After the GEMINI-ACS-1 trial [Turk Kardiyol Dern Ars]

Turk Kardiyol Dern Ars. 2017; 45(4): 8-9 | DOI: 10.5543/tkda.2017.52358

After the GEMINI-ACS-1 trial

Mehmet Birhan Yılmaz
Departmen of Cardiology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey

The GEMINI-ACS-1 trial has recently been published. It was designed to test whether low dose rivaroxaban as an antithrombotic agent is as safe as aspirin in patients with acute coronary syndromes(ACS). The trial is important to set light to future of ACS management.

Keywords: GEMINI-ACS-1, antithrombotic, acute coronary syndromes

How to cite this article
Mehmet Birhan Yılmaz. After the GEMINI-ACS-1 trial. Turk Kardiyol Dern Ars. 2017; 45(4): 8-9

Corresponding Author: Mehmet Birhan Yılmaz, France
Manuscript Language: Turkish

TOOLS Full Text PDF Print Download citation RIS EndNote BibTex Medlars Procite Reference Manager Share with email Share Send email to author Similar articles PubMed Google Scholar